Switch to:
Also traded in: France, Germany, Italy, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.55
SNY's Cash to Debt is ranked lower than
74% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.63 vs. SNY: 0.55 )
Ranked among companies with meaningful Cash to Debt only.
SNY' s Cash to Debt Range Over the Past 10 Years
Min: 0.14  Med: 9999.00 Max: N/A
Current: 0.55
Equity to Asset 0.57
SNY's Equity to Asset is ranked lower than
99.99% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. SNY: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
SNY' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.59 Max: 0.65
Current: 0.57
0.48
0.65
Interest Coverage 10.23
SNY's Interest Coverage is ranked lower than
75% of the 470 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 123.58 vs. SNY: 10.23 )
Ranked among companies with meaningful Interest Coverage only.
SNY' s Interest Coverage Range Over the Past 10 Years
Min: 7.88  Med: 11.37 Max: 19.65
Current: 10.23
7.88
19.65
WACC vs ROIC
8.29%
12.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 15.71
SNY's Operating margin (%) is ranked higher than
75% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.82 vs. SNY: 15.71 )
Ranked among companies with meaningful Operating margin (%) only.
SNY' s Operating margin (%) Range Over the Past 10 Years
Min: 15.25  Med: 17.95 Max: 20.7
Current: 15.71
15.25
20.7
Net-margin (%) 11.63
SNY's Net-margin (%) is ranked higher than
68% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.45 vs. SNY: 11.63 )
Ranked among companies with meaningful Net-margin (%) only.
SNY' s Net-margin (%) Range Over the Past 10 Years
Min: 7.92  Med: 13.59 Max: 18.02
Current: 11.63
7.92
18.02
ROE (%) 12.55
SNY's ROE (%) is ranked higher than
57% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. SNY: 12.55 )
Ranked among companies with meaningful ROE (%) only.
SNY' s ROE (%) Range Over the Past 10 Years
Min: 5.18  Med: 8.68 Max: 11.68
Current: 12.55
5.18
11.68
ROA (%) 7.20
SNY's ROA (%) is ranked higher than
58% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.67 vs. SNY: 7.20 )
Ranked among companies with meaningful ROA (%) only.
SNY' s ROA (%) Range Over the Past 10 Years
Min: 2.62  Med: 5.11 Max: 7.03
Current: 7.2
2.62
7.03
ROC (Joel Greenblatt) (%) 70.39
SNY's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.76 vs. SNY: 70.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SNY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 31.75  Med: 43.08 Max: 63.82
Current: 70.39
31.75
63.82
Revenue Growth (3Y)(%) -1.00
SNY's Revenue Growth (3Y)(%) is ranked lower than
72% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. SNY: -1.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SNY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.5  Med: 6.50 Max: 27.4
Current: -1
-1.5
27.4
EBITDA Growth (3Y)(%) -4.40
SNY's EBITDA Growth (3Y)(%) is ranked lower than
66% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. SNY: -4.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SNY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.2  Med: 5.70 Max: 35.7
Current: -4.4
-5.2
35.7
EPS Growth (3Y)(%) -8.10
SNY's EPS Growth (3Y)(%) is ranked lower than
68% of the 487 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. SNY: -8.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SNY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -12.8  Med: 3.40 Max: 41.4
Current: -8.1
-12.8
41.4
» SNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

SNY Guru Trades in Q1 2015

Paul Tudor Jones 7,598 sh (New)
NWQ Managers 3,927,517 sh (+33.50%)
John Buckingham 24,608 sh (+9.89%)
HOTCHKIS & WILEY 11,782,180 sh (+0.77%)
Charles Brandes 2,573,969 sh (+0.08%)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
David Dreman 1,102 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
Third Avenue Management Sold Out
Steven Cohen Sold Out
First Eagle Investment Sold Out
Ken Fisher 13,058,095 sh (-0.21%)
Murray Stahl 26,185 sh (-0.42%)
Scott Black 175,625 sh (-0.47%)
Dodge & Cox 43,034,073 sh (-0.55%)
James Barrow 30,225,221 sh (-1.88%)
Sarah Ketterer 477,367 sh (-5.81%)
PRIMECAP Management 3,972,907 sh (-7.33%)
Mario Gabelli 4,700 sh (-9.53%)
Manning & Napier Advisors, Inc 2,499,440 sh (-54.00%)
» More
Q2 2015

SNY Guru Trades in Q2 2015

Lee Ainslie 101,650 sh (New)
John Buckingham 132,190 sh (+437.18%)
Dodge & Cox 49,765,693 sh (+15.64%)
Manning & Napier Advisors, Inc 2,879,307 sh (+15.20%)
Sarah Ketterer 516,115 sh (+8.12%)
Scott Black 178,437 sh (+1.60%)
Ken Fisher 13,246,593 sh (+1.44%)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
David Dreman 1,102 sh (unchged)
Mario Gabelli 4,700 sh (unchged)
Paul Tudor Jones Sold Out
Charles Brandes 2,560,460 sh (-0.52%)
Murray Stahl 26,000 sh (-0.71%)
James Barrow 29,961,207 sh (-0.87%)
PRIMECAP Management 3,756,457 sh (-5.45%)
HOTCHKIS & WILEY 10,701,542 sh (-9.17%)
NWQ Managers 2,636,361 sh (-32.87%)
» More
Q3 2015

SNY Guru Trades in Q3 2015

Paul Tudor Jones 5,809 sh (New)
Sarah Ketterer 574,783 sh (+11.37%)
Murray Stahl 27,000 sh (+3.85%)
John Buckingham 133,116 sh (+0.70%)
Ken Fisher 13,295,966 sh (+0.37%)
Dodge & Cox 49,859,813 sh (+0.19%)
Mario Gabelli 4,700 sh (unchged)
Francis Chou 410,000 sh (unchged)
David Dreman 1,102 sh (unchged)
Lee Ainslie 101,650 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
Manning & Napier Advisors, Inc 2,819,031 sh (-2.09%)
Scott Black 173,432 sh (-2.80%)
James Barrow 29,123,564 sh (-2.80%)
NWQ Managers 2,501,826 sh (-5.10%)
Charles Brandes 2,290,031 sh (-10.56%)
HOTCHKIS & WILEY 9,035,695 sh (-15.57%)
PRIMECAP Management 2,939,082 sh (-21.76%)
» More
Q4 2015

SNY Guru Trades in Q4 2015

Murray Stahl 28,300 sh (+4.81%)
James Barrow 29,489,368 sh (+1.26%)
Ken Fisher 13,416,220 sh (+0.90%)
Dodge & Cox 49,915,073 sh (+0.11%)
Mario Gabelli 4,700 sh (unchged)
David Dreman Sold Out
Charles Brandes 2,198,827 sh (-3.98%)
PRIMECAP Management 2,767,582 sh (-5.84%)
John Buckingham 124,012 sh (-6.84%)
NWQ Managers 2,078,119 sh (-16.94%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Sanofi SA

Bill Nygren Comments on Sanofi - Apr 08, 2014

Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Sanofi SA

Weekly 3-Year Low Highlights: Sanofi, Exelon, Cummins, W.W. Grainger A look at companies whose stocks have recently reached their 3-year lows
According to GuruFocus list of 3-year lows, Sanofi (NYSE:SNY), Exelon Corp. (NYSE:EXC), Cummins Inc. (NYSE:CMI) and W.W. Grainger Inc. (NYSE:GWW) have all reached their three-year lows. Read more...
John Buckingham Buys 10 New Stakes in Second Quarter
John Buckingham (Trades, Portfolio), chief investment officer of AFAM (Al Frank Asset Management) Capital, which specializes in managing exchange-traded funds and equity portfolios, and editor of The Prudent Investor, an investment newsletter, learned the ropes from value investor Al Frank. The Al Frank Fund posted returns of 5.47% in 2014, 37.06% in 2013 and 17.26% in 2012. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.15
SNY's P/E(ttm) is ranked higher than
72% of the 783 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.27 vs. SNY: 17.15 )
Ranked among companies with meaningful P/E(ttm) only.
SNY' s P/E(ttm) Range Over the Past 10 Years
Min: 9.65  Med: 18.95 Max: 35.75
Current: 17.15
9.65
35.75
Forward P/E 11.81
SNY's Forward P/E is ranked higher than
77% of the 412 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.50 vs. SNY: 11.81 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 17.15
SNY's PE(NRI) is ranked higher than
74% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.00 vs. SNY: 17.15 )
Ranked among companies with meaningful PE(NRI) only.
SNY' s PE(NRI) Range Over the Past 10 Years
Min: 9.93  Med: 19.11 Max: 38.23
Current: 17.15
9.93
38.23
P/B 1.53
SNY's P/B is ranked higher than
73% of the 936 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. SNY: 1.53 )
Ranked among companies with meaningful P/B only.
SNY' s P/B Range Over the Past 10 Years
Min: 1.11  Med: 1.70 Max: 2.38
Current: 1.53
1.11
2.38
P/S 2.45
SNY's P/S is ranked higher than
54% of the 935 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. SNY: 2.45 )
Ranked among companies with meaningful P/S only.
SNY' s P/S Range Over the Past 10 Years
Min: 1.72  Med: 2.81 Max: 4.11
Current: 2.45
1.72
4.11
PFCF 36.54
SNY's PFCF is ranked lower than
59% of the 464 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.12 vs. SNY: 36.54 )
Ranked among companies with meaningful PFCF only.
SNY' s PFCF Range Over the Past 10 Years
Min: 15.02  Med: 33.15 Max: 82.54
Current: 36.54
15.02
82.54
POCF 26.49
SNY's POCF is ranked lower than
59% of the 633 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.66 vs. SNY: 26.49 )
Ranked among companies with meaningful POCF only.
SNY' s POCF Range Over the Past 10 Years
Min: 12.19  Med: 27.45 Max: 64.69
Current: 26.49
12.19
64.69
EV-to-EBIT 12.82
SNY's EV-to-EBIT is ranked higher than
69% of the 804 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.88 vs. SNY: 12.82 )
Ranked among companies with meaningful EV-to-EBIT only.
SNY' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.8  Med: 15.90 Max: 51.5
Current: 12.82
4.8
51.5
EV-to-EBITDA 7.86
SNY's EV-to-EBITDA is ranked higher than
81% of the 843 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.62 vs. SNY: 7.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.1  Med: 7.80 Max: 25.1
Current: 7.86
3.1
25.1
Shiller P/E 18.81
SNY's Shiller P/E is ranked higher than
78% of the 175 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.02 vs. SNY: 18.81 )
Ranked among companies with meaningful Shiller P/E only.
SNY' s Shiller P/E Range Over the Past 10 Years
Min: 11.49  Med: 19.68 Max: 28.3
Current: 18.81
11.49
28.3
Days Inventory 185.79
SNY's Days Inventory is ranked lower than
75% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.46 vs. SNY: 185.79 )
Ranked among companies with meaningful Days Inventory only.
SNY' s Days Inventory Range Over the Past 10 Years
Min: 155.87  Med: 184.87 Max: 378.1
Current: 185.79
155.87
378.1

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.13
SNY's Dividend Yield is ranked higher than
88% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. SNY: 4.13 )
Ranked among companies with meaningful Dividend Yield only.
SNY' s Dividend Yield Range Over the Past 10 Years
Min: 1.41  Med: 3.68 Max: 5.46
Current: 4.13
1.41
5.46
Dividend Payout 0.72
SNY's Dividend Payout is ranked lower than
87% of the 419 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. SNY: 0.72 )
Ranked among companies with meaningful Dividend Payout only.
SNY' s Dividend Payout Range Over the Past 10 Years
Min: 0.39  Med: 2.37 Max: 8.15
Current: 0.72
0.39
8.15
Dividend Growth (3y) 3.80
SNY's Dividend Growth (3y) is ranked lower than
57% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. SNY: 3.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SNY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 6.50 Max: 29.6
Current: 3.8
0
29.6
Forward Dividend Yield 4.13
SNY's Forward Dividend Yield is ranked higher than
87% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. SNY: 4.13 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 5.30
SNY's Yield on cost (5-Year) is ranked higher than
86% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.86 vs. SNY: 5.30 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SNY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.8  Med: 4.70 Max: 6.97
Current: 5.3
1.8
6.97
3-Year Average Share Buyback Ratio -0.10
SNY's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 462 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.90 vs. SNY: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.6  Med: -0.30 Max: 1.3
Current: -0.1
-24.6
1.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 58.18
SNY's Price/Tangible Book is ranked lower than
88% of the 898 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.67 vs. SNY: 58.18 )
Ranked among companies with meaningful Price/Tangible Book only.
SNY' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.48  Med: 13.35 Max: 2093.5
Current: 58.18
6.48
2093.5
Price/Projected FCF 1.31
SNY's Price/Projected FCF is ranked lower than
69% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.16 vs. SNY: 1.31 )
Ranked among companies with meaningful Price/Projected FCF only.
SNY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.9  Med: 1.99 Max: 20.75
Current: 1.31
0.9
20.75
Price/Median PS Value 0.89
SNY's Price/Median PS Value is ranked higher than
73% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.12 vs. SNY: 0.89 )
Ranked among companies with meaningful Price/Median PS Value only.
SNY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.64  Med: 1.08 Max: 2.69
Current: 0.89
0.64
2.69
Price/Graham Number 6.84
SNY's Price/Graham Number is ranked lower than
99.99% of the 685 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. SNY: 6.84 )
Ranked among companies with meaningful Price/Graham Number only.
SNY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.92  Med: 2.91 Max: 42.72
Current: 6.84
1.92
42.72
Earnings Yield (Greenblatt) (%) 7.78
SNY's Earnings Yield (Greenblatt) (%) is ranked higher than
51% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. SNY: 7.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SNY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.9  Med: 6.30 Max: 20.7
Current: 7.78
1.9
20.7
Forward Rate of Return (Yacktman) (%) -3.15
SNY's Forward Rate of Return (Yacktman) (%) is ranked lower than
51% of the 325 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.77 vs. SNY: -3.15 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SNY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -7.4  Med: 2.90 Max: 44.3
Current: -3.15
-7.4
44.3

More Statistics

Revenue(Mil) $40053
EPS $ 1.78
Beta0.99
Short Percentage of Float0.11%
52-Week Range $38.13 - 54.98
Shares Outstanding(Mil)2622.05

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 40,080 41,301 40,944
EPS($) 3.05 3.12 2.78
EPS without NRI($) 3.05 3.12 2.78

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:SAN.France, SNW.Germany, SANF.Italy, SNYN.Mexico, SAN.Switzerland, 0O59.UK, SNYNF.USA,
Sanofi SA was incorporated under the laws of France on April 28,1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
» More Articles for SNY

Headlines

Articles On GuruFocus.com
Dodge & Cox Global Stock Fund 4th Quarter Commentary Jan 19 2016 
Dodge & Cox Stock Fund 2015 Commentary Jan 18 2016 
Why MannKind Could Be a Value Trap Jan 04 2016 
Francis Chou's Holdings Trading at Low PE Dec 23 2015 
Warren Buffett Further Pares Munich Re Stake Dec 14 2015 
Weekly 3-Year Low Highlights: Sanofi, Exelon, Cummins, W.W. Grainger Nov 18 2015 
Why Warren Buffett Sold Munich Re Oct 06 2015 
MS Global Franchise Fund Reduces Positions in Sanofi, Diageo Sep 16 2015 
Third Avenue International Value Fund Part 2 Sep 10 2015 
Dodge & Cox Funds' 2015 Equity Mid-Year Review Aug 19 2015 

More From Other Websites
Regeneron Pharmaceuticals’ Major Revenue Sources in 4Q15 Feb 12 2016
AstraZeneca’s Valuation Report Card: How Did It Score? Feb 12 2016
Sanofi Earnings Analysis: Q4, 2015 By the Numbers Feb 12 2016
Sanofi -- Moody's: Europe's pharma companies' earnings growth looking less rosy in 2016 Feb 10 2016
Sanofi Tops Q4 Earnings, Revenues Fall Y/Y, Gives 2016 View Feb 10 2016
[$$] How a Sanofi Diabetes Bet Went Wrong Feb 10 2016
Regeneron Q4 Earnings Miss Estimates Amid Slow Praluent Launch Feb 09 2016
[$$] Sanofi Is Forced to End Latest Diabetes Effort Feb 09 2016
Sanofi gets shot in the arm from dollar strength Feb 09 2016
[$$] Sanofi upbeat on prospects for heart drug despite slow start in US Feb 09 2016
Regeneron: Get Used to Disappointment Feb 09 2016
Sanofi reports flat 2015 earnings Feb 09 2016
Sanofi reports flat 2015 earnings Feb 09 2016
Sanofi's Stock Dips Lower Following Q4 Print Feb 09 2016
Sanofi Delivered 2015 Business EPS up 8.5% on a Reported Basis and Stable at Constant Exchange Rates... Feb 09 2016
[$$] Regeneron Reports Slowing Sales Growth for Key Eye Drug Feb 09 2016
​Sanofi Genzyme revenues grow 20% in 2015 to top $4B Feb 09 2016
Sanofi gets shot in the arm from dollar strength Feb 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK